Rimadyl - How safe is it?
Posted on Saturday, May 05 @ 18:04:40 BST by jenvetadmin
|
We use Rimadyl commonly in practice but how safe is it? Do you warn you clients about possible side affects? We know about the dangers of using rimadyl long term for cats but there is allegedly also a large problem with dosing Labrador Retrievers.
New scientific information shows that Rimadyl can cause clotting conditions such as thrombosis, ischaemia and infarctions.
There is risk of liver failure with all NSAIDs. Liver necrosis in Labrador Retrievers caused by Rimadyl have been reported in the largest numbers. The manufacturer of Rimadyl alleges these reactions are attributed to the fact that Labs are the most common breed, and Rimadyl was the first and most commonly prescribed NSAID.
All NSAIDs have the potential to cause liver failure. Blood tests before administration of NSAIDs cannot predict this liver reaction. The risk of this reaction is small (1:10,000 with Rimadyl).
NSAIDs are relatively new to veterinary medicine. Veterinarians have little clinical experience with these drugs. Although every manufacturer has data that alleges their drug is safer than the others, no credible non-manufacturer-sponsored data exists which accurately compares these drugs.
LIST OF DOS AND DONT'S WHEN USING NSAIDS:
Do Monitor kidney and liver function if patients are using NSAID over a prolonged period.
Do Give Zantac or other antacid medication daily to prevent duodenal ulcers, a common side effect of all NSAIDs. Unfortunately this will not prevent gastric ulcers.
Do Give polysulfated glucosamines (PSGAs -- Adequan, Glycoflex, or Cosequin) with prolonged use of NSAIDs for arthritis and degenerative joint disease. NSAIDs relieve pain, but unfortunately over a long period of time NSAIDs can contribute to cartilage degeneration. PSGAs help cartilage to heal. NSAIDs can cause G.I. ulceration. PSGAs are part of the protectant lining of the G.I. tract. NSAIDs are better tolerated with PSGAs. PSGAs also protect the kidney.
Do Stop the medication at the first signs of gastric upset, nausea, lack of appetite, vomiting or diarrhea.
Never combine NSAIDs.
Do not give NSAIDs with steroids like dexamethazone, prednisolone, Vetalog or Depomedrol. Gastrointestinal ulceration and bleeding can result. A 3-to-5 day withdrawal period is necessary if you switch from one drug to another.
Do not give NSAIDs in patients with known impaired gastrointestinal, kidney, cardiovascular, or coagulation functions. If liver enzymes are elevated, use only at a lowered dose, and with liver treatment medication (i.e., SAM - E)
Do not give NSAIDs with Enalapril or other ACE inhibitors, Lasix, or with nephrotoxic drugs like aminoglycoside antibiotics or psychotropic drugs (Prozac, Clomiclam).
Do not give NSAIDs in dogs with Cushing's disease or other diseases where the patient is predisposed to thromboembolisms.
Do not use NSAIDs in trauma patients or critical care patients due to potential clotting problems and nephrotoxicity.
Relief from pain by NSAIDs is an individual response. If your patient does not get adequate relief from pain and return to normal function with one NSAID, it is worth trying a different NSAID.
Reactions to NSAIDs are comparable. If your patient has an adverse reaction to one NSAID, another NSAID should not be used. Another Class of pain reliever drugs should be used.
Click read more for the rest of this article:
These conditions have been previously excluded as a Rimadyl adverse reaction and Pfizer does not acknowledge the evidence (yet).
Rimadyl (Carprofen) is a cyclooxygenase-2 (COX-2) selective inhibitor in canine cells (Pfizer's own printed publications including studies of Ricketts et al.) Prostacyclin is a product of COX-2; it increases blood flow, reduces leukocyte adherence and inhibits platelet aggregation. Its inhibition increases the risk of acute vascular events in canines receiving COX-2 inhibitors (Hennan et al., 2001), and could promote thrombosis (Widlansky et al., 2003) which could lead to an infarction. Selective COX-2 inhibition blocks prostacyclin (PGI-2) formation without inhibiting TXA2 (thromboxane)(McAdam et al., 1999, and Catell-Lawson and Crofford, 2001), thereby increasing platelet activation, adhesion and aggregation with a resultant possibility for thrombosis and ISCHAEMIC events (Pitt et al., 2002).
Non-concomitant inhibition of COX-1 (for which Rimadyl does not inhibit) which mediates the actions of TXA2 (a platelet aggregating promoter) may increase the risk of thrombosis with selective COX-2 inhibitors (Christopher Jones, Veterinarian, Gulf Coast Veterinary Specialists, Houston, Texas).
This is but a brief sample of the scientific data, peer reviewed journal articles and publications by both scientists and veterinarians that point to the distinct possibilty of an clotting condition arising from the use of selective COX-2 inhibitors such as Rimadyl.
Etogesic, Dermaxx, Metacam and Zubrin all are NSAIDS under question. The action of these drugs is similar to aspirin, in that they inhibit inflammatory substances called prostaglandins (PGEs), which cause pain, inflammation, and fever.
These drugs are safer than aspirin because they are more selective for the harmful prostaglandins -- COX 2 PGEs -- and spare certain prostaglandins -- COX 1 PGEs -- which are essential to protect the G.I. tract, kidneys and other organs.
This is a sample sheet which many vets are giving to thier clients when dispensing Rimadly or other NSAIDS.These conditions have been previously excluded as a Rimadyl adverse reaction and Pfizer does not acknowledge the evidence (yet).
Rimadyl (Carprofen) is a cyclooxygenase-2 (COX-2) selective inhibitor in canine cells (Pfizer's own printed publications including studies of Ricketts et al.) Prostacyclin is a product of COX-2; it increases blood flow, reduces leukocyte adherence and inhibits platelet aggregation. Its inhibition increases the risk of acute vascular events in canines receiving COX-2 inhibitors (Hennan et al., 2001), and could promote thrombosis (Widlansky et al., 2003) which could lead to an infarction. Selective COX-2 inhibition blocks prostacyclin (PGI-2) formation without inhibiting TXA2 (thromboxane)(McAdam et al., 1999, and Catell-Lawson and Crofford, 2001), thereby increasing platelet activation, adhesion and aggregation with a resultant possibility for thrombosis and ISCHAEMIC events (Pitt et al., 2002).
Non-concomitant inhibition of COX-1 (for which Rimadyl does not inhibit) which mediates the actions of TXA2 (a platelet aggregating promoter) may increase the risk of thrombosis with selective COX-2 inhibitors (Christopher Jones, Veterinarian, Gulf Coast Veterinary Specialists, Houston, Texas).
This is but a brief sample of the scientific data, peer reviewed journal articles and publications by both scientists and veterinarians that point to the distinct possibilty of an clotting condition arising from the use of selective COX-2 inhibitors such as Rimadyl.
Etogesic, Dermaxx, Metacam and Zubrin all are NSAIDS under question. The action of these drugs is similar to aspirin, in that they inhibit inflammatory substances called prostaglandins (PGEs), which cause pain, inflammation, and fever.
These drugs are safer than aspirin because they are more selective for the harmful prostaglandins -- COX 2 PGEs -- and spare certain prostaglandins -- COX 1 PGEs -- which are essential to protect the G.I. tract, kidneys and other organs.
|
| |
|
Home
Veterinary News :
Veterinary Services:
